Abbvie sues US health agency over Botox

Core Viewpoint - Abbvie has filed a lawsuit against the U.S. Department of Health and Human Services, contesting the inclusion of Botox in the prescription drug price controls mandated by the Inflation Reduction Act of 2022 [1]. Group 1: Legal Action - The lawsuit was initiated in the federal court located in Washington, D.C. [1] - The Centers for Medicare & Medicaid Services (CMS) and its administrator Mehmet Oz are named as defendants in the lawsuit [1].